Buhl, Timo

[["dc.bibliographiccitation.journal","Frontiers in Microbiology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Taverne-Ghadwal, Liliane"],["dc.contributor.author","Kuhns, Martin"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Schulze, Marco H."],["dc.contributor.author","Mbaitolum, Weina Joseph"],["dc.contributor.author","Kersch, Lydia"],["dc.contributor.author","Weig, Michael"],["dc.contributor.author","Bader, Oliver"],["dc.contributor.author","Groß, U."],["dc.date.accessioned","2022-04-01T10:00:45Z"],["dc.date.available","2022-04-01T10:00:45Z"],["dc.date.issued","2022"],["dc.description.abstract","Oral candidiasis remains a common problem in HIV-infected individuals, especially in sub-Saharan Africa. Here, we performed the first study in Chad on the prevalence of oral yeasts carriage and oral candidiasis in HIV-positive subjects from southern Chad and analyzed the influence of HAART, CD4 + T-cell numbers, and antimycotics in 589 patients. These patients were recruited from a specialized medical center for HIV patients in Sarh and from a rural medical health dispensary in the vicinity, including a total of 384 HIV-positive and 205 HIV-negative individuals. Yeasts obtained from oral specimen were identified by MALDI-TOF MS and their antifungal susceptibility profiles determined. The overall prevalence of yeast colonization and symptomatic oral candidiasis in HIV-infected patients was 25.1%. The prevalence of oral candidiasis was higher in untreated than in HAART-treated HIV-positive patients (16% vs. 2%; p  < 0.01). Oral candidiasis was furthermore associated with high fungal burdens of Candida albicans and a CD4 + T-cell number <200/μl. A shift toward non -albicans Candida species was observed under nucleoside-based HAART therapy. Azole antifungal drug resistance was only observed for the intrinsically resistant species Candida krusei and Candida glabrata . Prevalence of oral candidiasis in the studied area was very low. The species distribution was similar to other countries around the world, with C. albicans being dominant. Candida dubliniensis was not isolated. Nucleoside-based HAART therapy significantly reduced oral colonization as well as occurrence of oral candidiasis caused by C. albicans and led to a species shift toward non- albicans species. Antifungal resistance was not yet a concern in Chad."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fmicb.2022.844069"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105503"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1664-302X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Epidemiology and Prevalence of Oral Candidiasis in HIV Patients From Chad in the Post-HAART Era"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","795"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","807"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Biedermann, Tilo"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Erpenbeck, Luise"],["dc.contributor.author","Eyerich, Kilian"],["dc.contributor.author","Eyerich, Stefanie"],["dc.contributor.author","Ghoreschi, Kamran"],["dc.contributor.author","Goebeler, Matthias"],["dc.contributor.author","Ludwig, Ralf J."],["dc.contributor.author","Schäkel, Knut"],["dc.contributor.author","Schilling, Bastian"],["dc.contributor.author","Schlapbach, Christoph"],["dc.contributor.author","Stary, Georg"],["dc.contributor.author","Stebut, Esther"],["dc.contributor.author","Steinbrink, Kerstin"],["dc.date.accessioned","2021-04-14T08:24:09Z"],["dc.date.available","2021-04-14T08:24:09Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary The COVID‐19 pandemic caused by SARS‐CoV‐2 has far‐reaching direct and indirect medical consequences. These include both the course and treatment of diseases. It is becoming increasingly clear that infections with SARS‐CoV‐2 can cause considerable immunological alterations, which particularly also affect pathogenetically and/or therapeutically relevant factors. Against this background we summarize here the current state of knowledge on the interaction of SARS‐CoV‐2/COVID‐19 with mediators of the acute phase of inflammation (TNF, IL‐1, IL‐6), type 1 and type 17 immune responses (IL‐12, IL‐23, IL‐17, IL‐36), type 2 immune reactions (IL‐4, IL‐13, IL‐5, IL‐31, IgE), B‐cell immunity, checkpoint regulators (PD‐1, PD‐L1, CTLA4), and orally druggable signaling pathways (JAK, PDE4, calcineurin). In addition, we discuss in this context non‐specific immune modulation by glucocorticosteroids, methotrexate, antimalarial drugs, azathioprine, dapsone, mycophenolate mofetil and fumaric acid esters, as well as neutrophil granulocyte‐mediated innate immune mechanisms. From these recent findings we derive possible implications for the therapeutic modulation of said immunological mechanisms in connection with SARS‐CoV‐2/COVID‐19. Although, of course, the greatest care should be taken with patients with immunologically mediated diseases or immunomodulating therapies, it appears that many treatments can also be carried out during the COVID‐19 pandemic; some even appear to alleviate COVID‐19."],["dc.identifier.doi","10.1111/ddg.14169"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81179"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","COVID‐19 and immunological regulations – from basic and translational aspects to clinical implications"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2021"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancer Immunology Immunotherapy"],["dc.bibliographiccitation.lastpage","2031"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Schardt, Anke"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Haenssle, Holger Andreas"],["dc.date.accessioned","2018-11-07T09:03:57Z"],["dc.date.available","2018-11-07T09:03:57Z"],["dc.date.issued","2012"],["dc.description.abstract","Availability of large quantities of functionally effective dendritic cells (DC) represents one of the major challenges for immunotherapeutic trials against infectious or malignant diseases. Low numbers or insufficient T-cell activation of DC may result in premature termination of treatment and unsatisfying immune responses in clinical trials. Based on the notion that cryopreservation of monocytes is superior to cryopreservation of immature or mature DC in terms of resulting DC quantity and immuno-stimulatory capacity, we aimed to establish an optimized protocol for the cryopreservation of highly concentrated peripheral blood mononuclear cells (PBMC) for DC-based immunotherapy. Cryopreserved cell preparations were analyzed regarding quantitative recovery, viability, phenotype, and functional properties. In contrast to standard isopropyl alcohol (IPA) freezing, PBMC cryopreservation in an automated controlled-rate freezer (CRF) with subsequent thawing and differentiation resulted in significantly higher cell yields of immature and mature DC. Immature DC yields and total protein content after using CRF were comparable with results obtained with freshly prepared PBMC and exceeded results of standard IPA freezing by approximately 50 %. While differentiation markers, allogeneic T-cell stimulation, viability, and cytokine profiles were similar to DC from standard freezing procedures, DC generated from CRF-cryopreserved PBMC induced a significantly higher antigen-specific IFN-gamma release from autologous effector T cells. In summary, automated controlled-rate freezing of highly concentrated PBMC represents an improved method for increasing DC yields and autologous T-cell stimulation."],["dc.description.sponsorship","University Medical Center Gottingen for young researchers"],["dc.identifier.doi","10.1007/s00262-012-1262-0"],["dc.identifier.isi","000310888400012"],["dc.identifier.pmid","22527251"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8798"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25006"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0340-7004"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Controlled-rate freezer cryopreservation of highly concentrated peripheral blood mononuclear cells results in higher cell yields and superior autologous T-cell stimulation for dendritic cell-based immunotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","350"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Contact Dermatitis"],["dc.bibliographiccitation.lastpage","360"],["dc.bibliographiccitation.volume","82"],["dc.contributor.affiliation","Reich, Anna; 1\r\nDepartment of Dermatology, Venereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Wilke, Annika; 2\r\nLower Saxony Institute of Occupational Dermatology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Gediga, Günther; 4\r\nDepartment of Dermatology, Environmental Medicine and Health Theory\r\nUniversity of Osnabrück\r\nOsnabrück Germany"],["dc.contributor.affiliation","Baurecht, Hansjörg; 6\r\nDepartment of Dermatology, Allergology and Venereology\r\nUniversity Hospital Schleswig‐Holstein\r\nKiel Germany"],["dc.contributor.affiliation","Rodríguez, Elke; 6\r\nDepartment of Dermatology, Allergology and Venereology\r\nUniversity Hospital Schleswig‐Holstein\r\nKiel Germany"],["dc.contributor.affiliation","Jakasa, Ivone; 8\r\nLaboratory for Analytical Chemistry, Department of Chemistry and Biochemistry, Faculty of Food Technology and Biotechnology\r\nUniversity of Zagreb\r\nZagreb Croatia"],["dc.contributor.affiliation","Geier, Johannes; 2\r\nLower Saxony Institute of Occupational Dermatology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Mempel, Martin; 1\r\nDepartment of Dermatology, Venereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Buhl, Timo; 1\r\nDepartment of Dermatology, Venereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Weidinger, Stephan; 6\r\nDepartment of Dermatology, Allergology and Venereology\r\nUniversity Hospital Schleswig‐Holstein\r\nKiel Germany"],["dc.contributor.affiliation","Kezic, Sanja; 10\r\nCoronel Institute of Occupational Health\r\nAmsterdam University Medical Center\r\nAmsterdam The Netherlands"],["dc.contributor.affiliation","John, Swen M.; 2\r\nLower Saxony Institute of Occupational Dermatology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.affiliation","Schön, Michael P.; 1\r\nDepartment of Dermatology, Venereology and Allergology\r\nUniversity Medical Center Göttingen\r\nGöttingen Germany"],["dc.contributor.author","Reich, Anna"],["dc.contributor.author","Wilke, Annika"],["dc.contributor.author","Gediga, Günther"],["dc.contributor.author","Baurecht, Hansjörg"],["dc.contributor.author","Rodríguez, Elke"],["dc.contributor.author","Jakasa, Ivone"],["dc.contributor.author","Geier, Johannes"],["dc.contributor.author","Mempel, Martin"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Weidinger, Stephan"],["dc.contributor.author","Kezic, Sanja"],["dc.contributor.author","John, Swen M."],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Brans, Richard"],["dc.date.accessioned","2020-12-10T18:27:14Z"],["dc.date.available","2020-12-10T18:27:14Z"],["dc.date.issued","2020"],["dc.date.updated","2022-02-09T13:21:55Z"],["dc.description.abstract","Abstract Background Metal work apprentices (MWAs) frequently develop work‐related hand eczema (HE). Objectives To evaluate the effect of health education on incidence of work‐related HE in MWAs and to assess confounding factors. Materials/methods In a prospective controlled intervention study, 131 MWAs received educational training on prevention of HE, whereas 172 MWAs and 118 office work apprentices served as controls. At baseline and during three yearly follow‐ups, questionnaires were completed and hands were examined. Saliva samples were collected for assessment of filaggrin (FLG) null mutations and an explorative genome‐wide association study (GWAS), and levels of various cytokines were assessed from stratum corneum samples. Results The 2‐year and 3‐year incidence of HE in the metalwork control group was 20.9% and 32.6%, respectively, which was significantly higher than in the intervention group (odds ratio [OR] 2.63, 95% confidence interval [CI] 1.31 to 5.28, P < .01 and OR 3.47, 95% CI 1.88 to 6.40, P < .0001). The knowledge score was higher in unaffected MWAs (P < .05). Other factors significantly associated with developing HE in MWAs were smoking cigarettes (P < .01) and FLG mutations (P < .001). No significant associations were found regarding epidermal cytokine levels and GWAS. Conclusions Health education is effective in primary prevention of HE in MWAs. Individual factors should be considered in targeted counseling."],["dc.description.sponsorship","Volkswagen Foundation http://dx.doi.org/10.13039/501100001663"],["dc.identifier.doi","10.1111/cod.13502"],["dc.identifier.eissn","1600-0536"],["dc.identifier.issn","0105-1873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76278"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.eissn","1600-0536"],["dc.relation.issn","0105-1873"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Health education decreases incidence of hand eczema in metal work apprentices: Results of a controlled intervention study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","815"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","824"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Beissert, Stefan"],["dc.contributor.author","Gaffal, Evelyn"],["dc.contributor.author","Goebeler, Matthias"],["dc.contributor.author","Hertl, Michael"],["dc.contributor.author","Mauch, Cornelia"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Schmidt, Enno"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Sticherling, Michael"],["dc.contributor.author","Sunderkötter, Cord"],["dc.contributor.author","Traidl‐Hoffmann, Claudia"],["dc.contributor.author","Werfel, Thomas"],["dc.contributor.author","Wilsman‐Theis, Dagmar"],["dc.contributor.author","Worm, Margitta"],["dc.date.accessioned","2021-04-14T08:24:08Z"],["dc.date.available","2021-04-14T08:24:08Z"],["dc.date.issued","2020"],["dc.description.abstract","Summary COVID‐19, caused by the coronavirus SARS‐CoV‐2, has become pandemic. A further level of complexity opens up as soon as we look at diseases whose pathogenesis and therapy involve different immunological signaling pathways, which are potentially affected by COVID‐19. Medical treatments must often be reassessed and questioned in connection with this infection. This article summarizes the current knowledge of COVID‐19 in the light of major dermatological and allergological diseases. It identifies medical areas lacking sufficient data and draws conclusions for the management of our patients during the pandemic. We focus on common chronic inflammatory skin diseases with complex immunological pathogenesis: psoriasis, eczema including atopic dermatitis, type I allergies, autoimmune blistering and inflammatory connective tissue diseases, vasculitis, and skin cancers. Since several other inflammatory skin diseases display related or comparable immunological reactions, clustering of the various inflammatory dermatoses into different disease patterns may help with therapeutic decisions. Thus, following these patterns of skin inflammation, our review may supply treatment recommendations and thoughtful considerations for disease management even beyond the most frequent diseases discussed here."],["dc.identifier.doi","10.1111/ddg.14195"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81174"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","COVID‐19 and implications for dermatological and allergological diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","569"],["dc.bibliographiccitation.journal","Frontiers in Neurology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Zimmermann, Julian"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Müller, Marcus"],["dc.date.accessioned","2019-07-09T11:44:37Z"],["dc.date.available","2019-07-09T11:44:37Z"],["dc.date.issued","2017"],["dc.description.abstract","Secondary autoimmunity is the most frequent adverse event occurring in almost every other alemtuzumab-treated multiple sclerosis patient. We report a case of a patient with relapsing-remitting multiple sclerosis who reported smooth, circular areas of complete hair loss on both thighs 6 months after the second treatment cycle with alemtuzumab. The patient was diagnosed as having alopecia areata (AA). Within 3 months, AA progressed to complete loss of all body hair (alopecia universalis). Current literature rarely connects alemtuzumab with the onset of alopecia of autoimmune origin. Here, we report a little-noticed autoimmune disease affecting the skin, very likely being associated with alemtuzumab. We emphasize the necessity of careful clinical surveillance of alemtuzumab- treated patients for yet undescribed autoimmune diseases."],["dc.identifier.doi","10.3389/fneur.2017.00569"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14844"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59052"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1664-2295"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","212"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Acta Dermato Venereologica"],["dc.bibliographiccitation.lastpage","213"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Buhl, Timo"],["dc.contributor.author","Wienrich, B. Gregor"],["dc.contributor.author","Sieblist, Claudia"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Seitz, Cornelia S."],["dc.date.accessioned","2018-11-07T08:46:50Z"],["dc.date.available","2018-11-07T08:46:50Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.2340/00015555-0800"],["dc.identifier.isi","000275977400028"],["dc.identifier.pmid","20169319"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7555"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20794"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Acta Dermato-venereologica"],["dc.relation.issn","0001-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Development of Segmental Superficial Actinic Porokeratosis during Immunosuppressive Therapy for Pemphigus Vulgaris"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","231"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","240"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Cevik, Naciye"],["dc.contributor.author","Schill, Tillmann"],["dc.contributor.author","Worm, Margitta"],["dc.contributor.author","Mahler, Vera"],["dc.contributor.author","Weisshaar, Elke"],["dc.contributor.author","Vieluf, Dieter"],["dc.contributor.author","Pfützner, Wolfgang"],["dc.contributor.author","Löffler, Harald"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Geier, Johannes"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2021-04-14T08:30:05Z"],["dc.date.available","2021-04-14T08:30:05Z"],["dc.date.issued","2021"],["dc.description.abstract","Summary Background The association of atopic dermatitis (AD) and allergic contact dermatitis has been a matter of considerable uncertainty. Study results range from lack of any association to increased sensitization for multiple allergens, but fail to identify consistent allergen associations. Objective We studied a large patch test cohort of patients stratified by their atopic skin diathesis using the Erlangen Atopy Score (EAS), independent of active skin disease. Methods Retrospective multi‐center data analysis from five departments of dermatology in Germany with 4,509 patients. Patients were grouped as “no atopic skin diathesis” (n = 2,165) and “atopic skin diathesis” (n = 1,743), according to EAS. Results Significantly more individuals with atopic skin diathesis showed at least one positive patch test reaction to the baseline series compared to individuals without atopic skin diathesis (49.1 % vs. 38.3 %). In logistic regression analyses, atopic skin diathesis was associated with a significantly higher risk of sensitization to methylchloroisothiazolinone/methylisothiazolinone (OR 2.383) and methylisothiazolinone (OR 1.891), thiuram mix (OR 1.614), as well as nickel (OR 1.530), cobalt (OR 1.683), and chromium (OR 2.089). Conclusions Atopic skin diathesis proved to be the most important intrinsic risk factor for contact sensitization to few, specific allergens. Past or present AD was a less relevant variable."],["dc.identifier.doi","10.1111/ddg.14341"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83096"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","Atopic skin diathesis rather than atopic dermatitis is associated with specific contact allergies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1488"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","1490"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Olbricht, Nadja"],["dc.contributor.author","Kromer, Christian"],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2021-04-14T08:22:55Z"],["dc.date.available","2021-04-14T08:22:55Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1111/ddg.14244"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80736"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."],["dc.title","Effective treatment of atopic dermatitis with dupilumab in an HIV‐positive patient"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","83"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","International Archives of Allergy and Immunology"],["dc.bibliographiccitation.lastpage","88"],["dc.bibliographiccitation.volume","178"],["dc.contributor.author","Saleh, Mohamed M."],["dc.contributor.author","Forkel, Susann"],["dc.contributor.author","Schön, Michael P."],["dc.contributor.author","Fuchs, Thomas"],["dc.contributor.author","Buhl, Timo"],["dc.date.accessioned","2020-12-10T18:37:51Z"],["dc.date.available","2020-12-10T18:37:51Z"],["dc.date.issued","2019"],["dc.description.abstract","Background: Natural rubber latex (NRL) allergy is commonly diagnosed according to medical history, skin allergy tests, and serological analyses. However, skin tests are increasingly being abandoned because of (i) their time-consuming nature, (ii) latex preparations for skin tests being not commercially available, and (iii) the use of in-house prepared test solutions is becoming ever more difficult due to increasing regulatory hurdles. In this light, we have evaluated differences in the profiles of current and former patients with suspected latex allergy. Methods: Sera of skin test-positive patients from a historic cohort (1995–2001, n = 149 patients) and currently (2014–2015, n = 48 patients) were simultaneously analyzed for specific IgE to latex by ImmunoCAP. If the serological screening was positive (≥0.35 kU/L), component-resolved diagnostics including profilins and cross-reactive carbohydrate determinants (CCDs) were performed. Results: In contrast to 88% (131/149) of the skin test-positive patients from the 1990s, only 51.1% (24/47) of the current cohort were found positive for specific IgE to latex. While 48.3% (72/149) of the patients had a convincing positive history in the 1990s, current skin test-positive patients rarely reported a relevant medical history (8.5%, 4/47). Specific IgE levels to latex were significantly higher in former patients with suspected latex allergy (p \\u0026lt; 0.001) than in former sensitized individuals without allergy. However, this significant difference was lost in current allergic and sensitized patients with positive skin tests. Conclusion: Sensitization profiles in patients with latex allergy have changed significantly over the last 2 decades. Discrimination between NRL sensitization and clinical allergy remains a diagnostic challenge. Our data highlight the need for a combination of all 3 criteria, i.e., patient history, skin test, and analysis of specific IgE, for a correct diagnosis of latex allergy."],["dc.identifier.doi","10.1159/000492191"],["dc.identifier.eissn","1423-0097"],["dc.identifier.issn","1018-2438"],["dc.identifier.pmid","30212836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77113"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0097"],["dc.relation.issn","1018-2438"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Profile Shift in Latex Sensitization over the Last 20 Years"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]